Blood condition may predict worse outcomes after heart attack
NCT ID NCT07615023
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study investigates whether a condition called clonal hematopoiesis of indeterminate potential (CHIP), which is an age-related change in blood cells, is linked to more severe heart damage in people who have had a major heart attack (STEMI). Researchers will test blood samples and use heart MRI scans in 350 patients to see if those with CHIP have worse outcomes, such as larger areas of heart damage or complications. The goal is to better understand risk factors for poor recovery after a heart attack.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If this study finds a link, it could point toward new ways to identify heart attack patients at higher risk for complications and guide future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will only show an association, not cause and effect. The results may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 350 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of adult female and male patients aged 18 to 75 years with a first acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention within 12 hours after symptom onset. Patients will be screened at the coronary care unit of the Medical University of Innsbruck. Eligible patients will be invited to participate after primary percutaneous coronary intervention and after assessment of inclusion and exclusion criteria. Standard clinical care and secondary prevention will be performed according to current guideline recommendations.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of first acute ST-elevation myocardial infarction according to current European Society of Cardiology guidelines * Symptoms consistent with ST-elevation myocardial infarction lasting more than 30 minutes and less than 12 hours before primary percutaneous coronary intervention * Treatment with primary percutaneous coronary intervention * Age 18 to 75 years * Written informed consent Exclusion Criteria: * Prior myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention * Persistent hemodynamic instability, Killip class greater than 2 including cardiogenic shock, or resuscitated cardiac arrest not allowing cardiac magnetic resonance imaging * Known active or prior malignancy, including hematologic malignancies or myelodysplastic syndromes * Prior oncologic treatment with chemotherapy, radiotherapy, or radioisotopes * Abnormal baseline complete blood count with clinically significant cytopenia, defined as leukocytes less than 3.0 x 10\^9/L, platelets less than 100 x 10\^9/L, or hemoglobin less than 10 g/dL * Chronic viral infection associated with systemic inflammation * Active autoimmune disease or chronic systemic inflammatory disorder * Chronic kidney disease with creatinine clearance less than 30 mL/min/1.73 m2 * Contraindication to cardiac magnetic resonance imaging * Pre-ST-elevation myocardial infarction life expectancy of less than 1 year * Participation in an interventional trial * Limited possibility to attend follow-up examinations, for example residence abroad * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clonal hematopoiesis of indeterminate potential (CHIP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Medical University of Innsbruck
Innsbruck, Tyrol, 6020, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI on your phone: the future of heart attack detection in the field?
- Can a Drug-Coated balloon beat a stent for tough heart attacks?
- A 15-Minute audio break: could guided imagery soothe heart patients?
- Can hidden blood mutations ignite heart disease?
- Are Europe's heart patients getting the right prevention care? a massive survey aims to find out
- Do complex heart procedures expose patients to more harmful radiation and contrast?